{"id":530,"date":"2026-08-03T14:47:39","date_gmt":"2026-08-03T13:47:39","guid":{"rendered":"https:\/\/peptidedeepdive.com\/?p=530"},"modified":"2026-09-23T16:20:31","modified_gmt":"2026-09-23T15:20:31","slug":"semaglutide","status":"publish","type":"post","link":"https:\/\/peptidedeepdive.com\/nl\/semaglutide\/","title":{"rendered":"Semaglutide Guide: FDA-Approved GLP-1 vs Research Peptides"},"content":{"rendered":"\n<meta charset=\"utf-8\">\n<meta content=\"width=device-width\" name=\"viewport\">\n\n\n<meta content=\"index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1\" name=\"robots\">\n<meta content=\"article\" property=\"og:type\">\n<meta content=\"PeptideDeepDive\" property=\"og:site_name\">\n<meta content=\"Semaglutide: FDA &amp; EU Approval, Safety &amp; Evidence (2026)\" property=\"og:title\">\n<meta content=\"Semaglutide explained: FDA\/EU approvals, Ozempic, Wegovy and Rybelsus, safety warnings, compounded products and research-grade differences.\" property=\"og:description\">\n<meta content=\"https:\/\/peptidedeepdive.com\/semaglutide\/\" property=\"og:url\">\n<meta content=\"https:\/\/d8j0ntlcm91z4.cloudfront.net\/user_3GYMvT1tR5HC1gvee5MuSPX1OIk\/hf_20260822_174024_acbbc755-85e2-4aa2-92b1-e90882012db7.png\" property=\"og:image\">\n<meta content=\"2026-09-21T00:00:00+03:00\" property=\"article:modified_time\">\n<meta content=\"summary_large_image\" name=\"twitter:card\">\n<meta content=\"Semaglutide: FDA &amp; EU Approval, Safety &amp; Evidence (2026)\" name=\"twitter:title\">\n<meta content=\"Semaglutide explained: FDA\/EU approvals, Ozempic, Wegovy and Rybelsus, safety warnings, compounded products and research-grade differences.\" name=\"twitter:description\">\n<meta content=\"PeptideDeepDive Editorial Team\" name=\"twitter:data1\">\n<meta content=\"11 minutes\" name=\"twitter:data2\">\n<meta content=\"Written by\" name=\"twitter:label1\">\n<meta content=\"Est. reading time\" name=\"twitter:label2\">\n\n<link as=\"image\" href=\"https:\/\/d8j0ntlcm91z4.cloudfront.net\/user_3GYMvT1tR5HC1gvee5MuSPX1OIk\/hf_20260822_174024_acbbc755-85e2-4aa2-92b1-e90882012db7.png\" rel=\"preload\">\n<script type=\"application\/ld+json\">\n{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/peptidedeepdive.com\/semaglutide\/#article\",\"headline\":\"Semaglutide: FDA & EU Approval, Safety & Evidence (2026)\",\"description\":\"Semaglutide explained: FDA\/EU approvals, Ozempic, Wegovy and Rybelsus, safety warnings, compounded products and research-grade differences.\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/peptidedeepdive.com\/semaglutide\/\"},\"image\":\"https:\/\/d8j0ntlcm91z4.cloudfront.net\/user_3GYMvT1tR5HC1gvee5MuSPX1OIk\/hf_20260822_174024_acbbc755-85e2-4aa2-92b1-e90882012db7.png\",\"author\":{\"@type\":\"Organization\",\"name\":\"PeptideDeepDive Editorial Team\",\"url\":\"https:\/\/peptidedeepdive.com\/about\/\"},\"publisher\":{\"@type\":\"Organization\",\"name\":\"PeptideDeepDive\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png\"}},\"dateModified\":\"2026-09-21\",\"inLanguage\":\"en-GB\",\"about\":[\"Semaglutide\",\"GLP-1 receptor agonists\",\"Ozempic\",\"Wegovy\",\"Rybelsus\",\"FDA approval\",\"European medicines regulation\",\"Compounded semaglutide\"],\"isAccessibleForFree\":true,\"citation\":[\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215256s033lbl.pdf\",\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wegovy\",\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ozempic\",\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rybelsus\",\"https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize\",\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list\",\"https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss\",\"https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy\"]},{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/peptidedeepdive.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research\",\"item\":\"https:\/\/peptidedeepdive.com\/research\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Semaglutide guide\",\"item\":\"https:\/\/peptidedeepdive.com\/semaglutide\/\"}]},{\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Is semaglutide FDA-approved?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes. FDA-approved semaglutide products include Ozempic, Rybelsus and Wegovy for specific labelled uses. Approval does not cover every product sold as semaglutide.\"}},{\"@type\":\"Question\",\"name\":\"Is semaglutide approved in Europe?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes. The EU has authorised Ozempic, Rybelsus and Wegovy. As of 2026, Wegovy's EU authorisation also includes oral tablets for adults, alongside the injectable form.\"}},{\"@type\":\"Question\",\"name\":\"Is semaglutide a peptide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Semaglutide is a peptide-based GLP-1 receptor agonist. An approved semaglutide medicine is not the same regulatory category as an unapproved research product.\"}},{\"@type\":\"Question\",\"name\":\"How is semaglutide different from research-grade peptides?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Approved semaglutide medicines have regulator-reviewed clinical evidence, defined manufacturing controls, prescribing information and post-market safety monitoring. A research-use label does not provide those medicine approvals or quality guarantees.\"}},{\"@type\":\"Question\",\"name\":\"What is the difference between semaglutide and tirzepatide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. Their approved products, labels and evidence are not interchangeable.\"}}]}]}\n<\/script>\n<link href=\"https:\/\/fonts.googleapis.com\" rel=\"preconnect\">\n<link crossorigin=\"\" href=\"https:\/\/fonts.gstatic.com\" rel=\"preconnect\">\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=IBM+Plex+Mono:wght@600&amp;display=swap\" rel=\"stylesheet\">\n<style>\n  :root{\n    --black:#0B0D0C; --near-black:#111412; --white:#FFFFFF; --gray-bg:#F5F6F4;\n    --line:#E4E6E1; --text-soft:#6B6F6C; --emerald-bright:#92B9A4; --emerald-pale:#E9F1ED;\n    --emerald-deep:#456C57; --max-w:800px;\n  }\n  *{box-sizing:border-box;}\n  body{margin:0; background:#fff; color:#0B0D0C; font-family:'Helvetica Neue', Helvetica, Arial, sans-serif; font-size:16px; line-height:1.65;}\n  a{color:var(--emerald-deep);}\n  .wrap{max-width:var(--max-w); margin:0 auto; padding:0 24px;}\n  .mono{font-family:'IBM Plex Mono', monospace;}\n  .nav{position:sticky; top:0; z-index:40; background:rgba(11,13,12,0.95); backdrop-filter:blur(8px);}\n  .nav .wrap{max-width:1152px; display:flex; align-items:center; justify-content:space-between; padding:16px 24px;}\n  .brand{display:flex; align-items:center; gap:9px; color:#fff; font-weight:600; font-size:1.1rem; text-decoration:none;}\n  .brand-logo{height:30px; width:30px; object-fit:contain;}\n  .nav-links{display:flex; gap:32px; font-size:14px; color:rgba(255,255,255,0.65);}\n  .nav-links a{text-decoration:none; color:inherit;}\n  @media (max-width:760px){ .nav-links{display:none;} }\n  .article-hero{padding:56px 0 8px;}\n  .breadcrumb{font-size:13px; color:var(--text-soft); margin-bottom:24px;}\n  .breadcrumb a{color:var(--text-soft); text-decoration:none;}\n  .r-badge{display:inline-flex; font-size:11px; font-weight:700; letter-spacing:0.05em; text-transform:uppercase; color:var(--emerald-deep); background:var(--emerald-pale); padding:5px 12px; border-radius:100px; margin-bottom:18px;}\n  h1{font-weight:600; letter-spacing:-0.02em; font-size:clamp(1.9rem,4.4vw,2.6rem); line-height:1.14; margin:0 0 18px;}\n  .dek{font-size:18px; color:var(--text-soft); max-width:64ch; margin:0 0 24px;}\n  .article-meta{font-size:13px; color:var(--text-soft); font-weight:600; padding-bottom:32px; border-bottom:1px solid var(--line); margin-bottom:24px;}\n  .hero-img{width:100%; aspect-ratio:16\/9; height:auto; object-fit:cover; border-radius:16px; display:block; margin:0 0 10px; background:var(--gray-bg);}\n  .hero-caption{font-size:13px; color:var(--text-soft); font-style:italic; margin:0 0 40px;}\n  article h2{font-size:1.5rem; font-weight:600; letter-spacing:-0.01em; margin:44px 0 16px;}\n  article h3{font-size:1.1rem; font-weight:600; margin:28px 0 12px;}\n  article p{color:var(--text-soft); font-size:16.5px; line-height:1.75; margin:0 0 18px;}\n  article strong{color:var(--black); font-weight:600;}\n  .toc{background:var(--gray-bg); border:1px solid var(--line); border-radius:16px; padding:22px 26px; margin:0 0 36px;}\n  .toc p{font-size:11px; font-weight:700; letter-spacing:.08em; text-transform:uppercase; color:var(--emerald-deep); margin:0 0 10px;}\n  .toc ol{margin:0; padding-left:20px; font-size:14.5px; color:var(--text-soft);}\n  .toc li{margin-bottom:6px;}\n  .toc a{color:var(--text-soft); text-decoration:none;}\n  article table{width:100%; border-collapse:collapse; margin:24px 0; font-size:14px;}\n  article th, article td{text-align:left; padding:12px 14px; border-bottom:1px solid var(--line); color:var(--text-soft); vertical-align:top;}\n  article th{color:var(--black); font-weight:600; font-size:12px; text-transform:uppercase; background:var(--gray-bg);}\n  .info-row{display:grid; grid-template-columns:repeat(3,1fr); gap:14px; margin:24px 0;}\n  .info-box{background:var(--gray-bg); border:1px solid var(--line); border-radius:16px; padding:18px 20px;}\n  .info-box .label{font-size:12px; font-weight:700; color:var(--emerald-deep); margin-bottom:8px;}\n  .info-box strong{display:block; margin-bottom:4px;}\n  .info-box span{font-size:13.5px; color:var(--text-soft);}\n  @media (max-width:700px){ .info-row{grid-template-columns:1fr;} }\n  .steps-row{display:flex; gap:10px; flex-wrap:wrap; margin:24px 0;}\n  .step-pill{background:var(--emerald-pale); color:var(--emerald-deep); font-family:'IBM Plex Mono',monospace; font-weight:600; font-size:13px; padding:8px 16px; border-radius:100px;}\n  .timeline{border-left:2px solid var(--line); margin:28px 0; padding-left:0;}\n  .t-item{position:relative; padding:0 0 36px 26px;}\n  .t-item:last-child{padding-bottom:0;}\n  .t-item::before{content:\"\"; position:absolute; left:-7px; top:4px; width:12px; height:12px; border-radius:50%; background:var(--emerald-bright); border:2px solid #fff; outline:1px solid var(--emerald-deep);}\n  .t-date{font-family:'IBM Plex Mono',monospace; font-size:13px; color:var(--emerald-deep); font-weight:600; margin-bottom:6px;}\n  .t-item h3{margin:0 0 10px; font-size:1.1rem;}\n  .t-item p{margin:0 0 14px; font-size:15px;}\n  .t-img{width:100%; aspect-ratio:16\/9; height:auto; object-fit:cover; border-radius:14px; display:block; background:var(--gray-bg);}\n  .callout{background:var(--black); color:#fff; border-radius:18px; padding:26px 28px; margin:32px 0;}\n  .callout .label{font-size:11.5px; font-weight:700; letter-spacing:0.08em; text-transform:uppercase; color:var(--emerald-bright); margin-bottom:12px;}\n  .callout p{color:rgba(255,255,255,0.7); margin:0; font-size:14.5px;}\n  .split-row{display:grid; grid-template-columns:1fr 1fr; gap:16px; margin:24px 0;}\n  .split-box{border:1px solid var(--line); border-radius:16px; padding:22px;}\n  .split-box h3{margin:0 0 8px; font-size:1.05rem;}\n  .split-box p{margin:0; font-size:14.5px;}\n  @media (max-width:600px){ .split-row{grid-template-columns:1fr;} }\n  .faq-item{border-bottom:1px solid var(--line); padding:18px 0;}\n  .faq-item:first-of-type{border-top:1px solid var(--line);}\n  .faq-item h3{margin:0 0 8px; font-size:16px;}\n  .faq-item p{margin:0; font-size:15px; color:var(--text-soft);}\n  .related-products{margin:48px 0 18px;}\n  .related-products h2{font-size:1.35rem; margin:0 0 8px;}\n  .related-intro{max-width:66ch; color:var(--text-soft); font-size:14.5px; line-height:1.65; margin:0 0 18px;}\n  .product-grid{display:grid; grid-template-columns:repeat(3,minmax(0,1fr)); gap:14px;}\n  .product-card{display:flex; flex-direction:column; min-width:0; overflow:hidden; background:#fff; border:1px solid var(--line); border-radius:16px;}\n  .product-image-wrap{aspect-ratio:1\/1; margin:7px 7px 0; overflow:hidden; background:#fff; border:1px solid var(--line); border-radius:12px;}\n  .product-card .product-image{display:block; width:100%; height:100%; object-fit:contain; border-radius:11px;}\n  .product-copy{display:flex; flex:1; flex-direction:column; padding:15px;}\n  .product-label{min-height:32px; color:var(--emerald-deep); font-size:10.5px; font-weight:700; letter-spacing:.05em; line-height:1.45; text-transform:uppercase;}\n  .product-card h3{min-height:45px; color:var(--black); font-size:1rem; line-height:1.35; margin:6px 0;}\n  .product-card p{min-height:57px; color:var(--text-soft); font-size:12px; line-height:1.5; margin:0 0 9px;}\n  .product-price{color:var(--black); font-size:16px; font-weight:600; margin:0 0 12px;}\n  .product-actions{display:grid; gap:7px; margin-top:auto;}\n  .product-button,.product-guide{display:flex; align-items:center; justify-content:center; min-height:42px; padding:10px 12px; border-radius:100px; font-size:12.5px; font-weight:600; line-height:1.2; text-align:center; text-decoration:none;}\n  .product-button{background:var(--black); color:#fff;}\n  .product-button:hover{background:var(--emerald-deep);}\n  .product-guide{background:#fff; color:var(--black); border:1px solid var(--line);}\n  .product-guide:hover{color:var(--emerald-deep); border-color:var(--emerald-deep);}\n  .affiliate-note{color:var(--text-soft); font-size:11.5px; line-height:1.55; margin:13px 0 0;}\n  @media (max-width:700px){.product-grid{grid-template-columns:1fr;}.product-card{display:grid; grid-template-columns:120px 1fr;}.product-image-wrap{aspect-ratio:1\/1; margin:7px;}.product-card h3,.product-label,.product-card p{min-height:0;}}\n  @media (max-width:420px){.product-card{display:flex;}.product-image-wrap{aspect-ratio:16\/10;}}\n  .refs{margin-top:50px; padding-top:28px; border-top:1px solid var(--line); padding-bottom:50px;}\n  .refs ol{padding-left:20px; margin:0; font-size:13px; color:var(--text-soft);}\n  .refs li{margin-bottom:10px;}\n  footer{background:var(--black); border-top:1px solid rgba(255,255,255,0.08);}\n  footer .wrap{max-width:1152px; display:flex; align-items:center; justify-content:space-between; flex-wrap:wrap; gap:20px; padding:40px 24px;}\n  footer p{color:rgba(255,255,255,0.35); font-size:12px; max-width:420px; text-align:right; margin:0;}\n\n\n  \/* ---------- MOBILE EXPERIENCE POLISH ---------- *\/\n\n  .menu-button{\n    display:none;\n    align-items:center;\n    justify-content:center;\n    width:44px;\n    height:44px;\n    padding:0;\n    color:#fff;\n    background:transparent;\n    border:1px solid rgba(255,255,255,.22);\n    border-radius:10px;\n    cursor:pointer;\n  }\n\n  .menu-button svg{\n    width:21px;\n    height:21px;\n    fill:none;\n    stroke:currentColor;\n    stroke-width:2;\n    stroke-linecap:round;\n  }\n\n  .mobile-nav{display:none;}\n  .table-scroll{width:100%;max-width:100%;}\n\n  @media (max-width:760px){\n    .nav .wrap{\n      position:relative;\n      min-height:64px;\n      padding:10px 20px;\n    }\n\n    .brand{\n      min-width:0;\n      gap:8px;\n      font-size:1rem;\n    }\n\n    .brand-logo{\n      width:28px;\n      height:28px;\n    }\n\n    .menu-button{\n      display:inline-flex;\n      flex:0 0 44px;\n    }\n\n    .mobile-nav{\n      position:absolute;\n      top:100%;\n      right:20px;\n      left:20px;\n      z-index:60;\n      max-height:calc(100vh - 64px);\n      max-height:calc(100svh - 64px);\n      padding:8px 12px 12px;\n      overflow-y:auto;\n      overscroll-behavior:contain;\n      background:rgba(11,13,12,.99);\n      border:1px solid rgba(255,255,255,.1);\n      border-top:0;\n      border-radius:0 0 14px 14px;\n      box-shadow:0 14px 30px rgba(0,0,0,.22);\n    }\n\n    .mobile-nav.open{display:grid;}\n\n    .mobile-nav a{\n      display:flex;\n      align-items:center;\n      min-height:48px;\n      padding:11px 10px;\n      color:rgba(255,255,255,.82);\n      text-decoration:none;\n      border-bottom:1px solid rgba(255,255,255,.08);\n    }\n\n    .mobile-nav a:last-child{border-bottom:0;}\n\n    .mobile-nav a:hover,\n    .mobile-nav a:focus-visible{\n      color:#fff;\n      background:rgba(255,255,255,.06);\n    }\n\n    .wrap{\n      padding-left:20px;\n      padding-right:20px;\n    }\n\n    .article-hero{\n      padding:48px 0 6px;\n    }\n\n    .breadcrumb{\n      margin-bottom:18px;\n      font-size:12px;\n      line-height:1.5;\n    }\n\n    .r-badge{\n      margin-bottom:14px;\n      font-size:10.5px;\n      line-height:1.4;\n    }\n\n    h1{\n      margin-bottom:16px;\n      font-size:clamp(2rem,8vw,2.6rem);\n      line-height:1.08;\n    }\n\n    .dek{\n      margin-bottom:20px;\n      font-size:16px;\n      line-height:1.65;\n    }\n\n    .article-meta{\n      margin-bottom:22px;\n      padding-bottom:22px;\n      font-size:12px;\n      line-height:1.5;\n    }\n\n    .hero-img{\n      max-height:330px;\n      margin-bottom:8px;\n      border-radius:14px;\n    }\n\n    .hero-caption{\n      margin-bottom:28px;\n      font-size:12.5px;\n      line-height:1.55;\n    }\n\n    .toc{\n      padding:16px;\n      margin-bottom:28px;\n      overflow:hidden;\n      border-radius:14px;\n    }\n\n    .toc p{\n      margin-bottom:10px;\n    }\n\n    .toc ol{\n      display:flex;\n      gap:8px;\n      width:100%;\n      margin:0;\n      padding:2px 0 4px;\n      overflow-x:auto;\n      list-style:none;\n      overscroll-behavior-inline:contain;\n      scroll-snap-type:x proximity;\n      -webkit-overflow-scrolling:touch;\n      scrollbar-width:none;\n    }\n\n    .toc ol::-webkit-scrollbar{display:none;}\n\n    .toc li{\n      flex:0 0 auto;\n      margin:0;\n      scroll-snap-align:start;\n    }\n\n    .toc a{\n      display:flex;\n      align-items:center;\n      min-height:40px;\n      padding:9px 12px;\n      white-space:nowrap;\n      background:#fff;\n      border:1px solid var(--line);\n      border-radius:999px;\n      font-size:12px;\n      line-height:1.25;\n    }\n\n    article h2{\n      margin:40px 0 13px;\n      font-size:1.36rem;\n      line-height:1.28;\n      scroll-margin-top:88px;\n    }\n\n    article h3{\n      margin:22px 0 10px;\n      font-size:1rem;\n      line-height:1.4;\n    }\n\n    article p{\n      margin-bottom:16px;\n      font-size:15.5px;\n      line-height:1.7;\n    }\n\n    .info-row{\n      gap:10px;\n      margin:22px 0;\n    }\n\n    .info-box{\n      padding:17px;\n      border-radius:14px;\n    }\n\n    .info-box .label{\n      margin-bottom:6px;\n    }\n\n    .table-scroll{\n      margin:22px 0 30px;\n      overflow-x:auto;\n      overscroll-behavior-inline:contain;\n      -webkit-overflow-scrolling:touch;\n      border:1px solid var(--line);\n      border-radius:13px;\n    }\n\n    .table-scroll table{\n      min-width:760px;\n      width:100%;\n      margin:0;\n      border-collapse:collapse;\n    }\n\n    .table-scroll th,\n    .table-scroll td{\n      padding:11px 12px;\n      font-size:13px;\n    }\n\n    .table-scroll thead th:first-child{\n      min-width:120px;\n    }\n\n    .steps-row{\n      gap:8px;\n      margin:22px 0;\n    }\n\n    .step-pill{\n      display:inline-flex;\n      align-items:center;\n      min-height:40px;\n      padding:8px 13px;\n      font-size:12px;\n    }\n\n    .timeline{\n      margin:24px 0;\n    }\n\n    .t-item{\n      padding:0 0 30px 22px;\n    }\n\n    .t-date{\n      font-size:12px;\n    }\n\n    .t-item h3{\n      font-size:1rem;\n      line-height:1.4;\n    }\n\n    .t-item p{\n      font-size:14.5px;\n      line-height:1.68;\n    }\n\n    .t-img{\n      max-height:300px;\n      border-radius:13px;\n    }\n\n    .callout{\n      padding:22px;\n      margin:28px 0;\n      border-radius:16px;\n    }\n\n    .callout p{\n      font-size:14.5px;\n      line-height:1.65;\n    }\n\n    .split-row{\n      gap:12px;\n      margin:22px 0;\n    }\n\n    .split-box{\n      padding:18px;\n      border-radius:14px;\n    }\n\n    .split-box p{\n      font-size:13.8px;\n      line-height:1.65;\n    }\n\n    .faq-item{\n      padding:16px 0;\n    }\n\n    .faq-item h3{\n      font-size:15.5px;\n      line-height:1.4;\n    }\n\n    .faq-item p{\n      font-size:14px;\n      line-height:1.65;\n    }\n\n    .refs{\n      margin-top:42px;\n      padding-top:24px;\n      padding-bottom:48px;\n    }\n\n    .refs li{\n      font-size:12px;\n      line-height:1.65;\n    }\n\n    .related-products{\n      margin:36px 0 18px;\n    }\n\n    .related-products h2{\n      font-size:1.24rem;\n      line-height:1.3;\n    }\n\n    .related-intro{\n      font-size:13.5px;\n      line-height:1.65;\n    }\n\n    .product-grid{\n      gap:12px;\n    }\n\n    .product-card{\n      border-radius:14px;\n    }\n\n    .product-copy{\n      padding:14px;\n    }\n\n    .product-button,\n    .product-guide{\n      min-height:44px;\n      padding:10px 12px;\n    }\n\n    footer .wrap{\n      gap:16px;\n      padding:30px 20px;\n    }\n\n    footer p{\n      line-height:1.6;\n    }\n  }\n\n  @media (max-width:560px){\n    .nav .wrap{\n      min-height:62px;\n      padding:9px 16px;\n    }\n\n    .brand{\n      font-size:.96rem;\n    }\n\n    .brand-logo{\n      width:26px;\n      height:26px;\n    }\n\n    .menu-button{\n      width:42px;\n      height:42px;\n      flex-basis:42px;\n    }\n\n    .mobile-nav{\n      right:16px;\n      left:16px;\n    }\n\n    .wrap{\n      padding-left:16px;\n      padding-right:16px;\n    }\n\n    .article-hero{\n      padding-top:40px;\n    }\n\n    .breadcrumb{\n      margin-bottom:15px;\n      font-size:11.5px;\n    }\n\n    .r-badge{\n      margin-bottom:12px;\n      font-size:10px;\n    }\n\n    h1{\n      font-size:clamp(1.82rem,9vw,2.16rem);\n    }\n\n    .dek{\n      margin-bottom:18px;\n      font-size:15px;\n    }\n\n    .article-meta{\n      font-size:11.5px;\n    }\n\n    .hero-img{\n      max-height:255px;\n      border-radius:12px;\n    }\n\n    .hero-caption{\n      margin-bottom:24px;\n      font-size:12px;\n    }\n\n    .toc{\n      padding:14px;\n      margin-bottom:24px;\n    }\n\n    .toc a{\n      min-height:42px;\n    }\n\n    article h2{\n      margin-top:34px;\n      font-size:1.2rem;\n    }\n\n    article h3{\n      font-size:.98rem;\n    }\n\n    article p{\n      font-size:14.5px;\n      line-height:1.68;\n    }\n\n    .info-row{\n      grid-template-columns:1fr;\n    }\n\n    .info-box{\n      padding:16px;\n    }\n\n    .table-scroll table{\n      min-width:720px;\n    }\n\n    .table-scroll th,\n    .table-scroll td{\n      padding:10px 11px;\n      font-size:12.5px;\n    }\n\n    .steps-row{\n      display:grid;\n      grid-template-columns:1fr;\n    }\n\n    .step-pill{\n      justify-content:flex-start;\n      min-height:42px;\n    }\n\n    .timeline{\n      margin-top:22px;\n    }\n\n    .t-item{\n      padding-left:20px;\n      padding-bottom:26px;\n    }\n\n    .t-img{\n      max-height:240px;\n      border-radius:12px;\n    }\n\n    .callout{\n      padding:18px;\n      margin:24px 0;\n    }\n\n    .split-row{\n      grid-template-columns:1fr;\n    }\n\n    .split-box{\n      padding:16px;\n    }\n\n    .faq-item p{\n      font-size:13.8px;\n    }\n\n    .refs{\n      margin-top:36px;\n      padding-bottom:42px;\n    }\n\n    .refs li{\n      font-size:11.8px;\n    }\n\n    .product-grid{\n      grid-template-columns:1fr;\n    }\n\n    .product-card{\n      display:grid;\n      grid-template-columns:104px minmax(0,1fr);\n    }\n\n    .product-image-wrap{\n      aspect-ratio:1\/1;\n    }\n\n    .product-copy{\n      padding:13px;\n    }\n\n    .product-card h3,\n    .product-label,\n    .product-card p{\n      min-height:0;\n    }\n\n    .product-card h3{\n      font-size:15px;\n    }\n\n    .product-card p{\n      font-size:12px;\n    }\n\n    .affiliate-note{\n      font-size:11px;\n      line-height:1.6;\n    }\n\n    footer .wrap{\n      flex-direction:column;\n      padding:28px 16px;\n      text-align:center;\n    }\n\n    footer p{\n      text-align:center;\n    }\n  }\n\n  @media (max-width:420px){\n    .product-card{\n      display:flex;\n    }\n\n    .product-image-wrap{\n      aspect-ratio:16\/10;\n    }\n  }\n\n  @media (max-width:380px){\n    .nav .wrap{\n      padding-left:14px;\n      padding-right:14px;\n    }\n\n    .brand{\n      font-size:.92rem;\n    }\n\n    .mobile-nav{\n      right:14px;\n      left:14px;\n    }\n\n    .wrap{\n      padding-left:14px;\n      padding-right:14px;\n    }\n\n    h1{\n      font-size:1.7rem;\n    }\n\n    .dek{\n      font-size:14.5px;\n    }\n\n    .toc,\n    .info-box,\n    .callout,\n    .split-box{\n      padding-left:15px;\n      padding-right:15px;\n    }\n\n    footer .wrap{\n      padding-left:14px;\n      padding-right:14px;\n    }\n  }\n\n\n<\/style>\n<div class=\"nav\">\n<div class=\"wrap\">\n<a class=\"brand\" href=\"https:\/\/peptidedeepdive.com\/\"><img data-recalc-dims=\"1\" loading=\"lazy\" alt=\"PeptideDeepDive logo\" class=\"brand-logo\" decoding=\"async\" height=\"30\" src=\"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=30%2C30&#038;ssl=1\" width=\"30\">PeptideDeepDive<\/a>\n<div class=\"nav-links\">\n<a href=\"https:\/\/peptidedeepdive.com\/research\/\">Research<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/peptide-coas\/\">Lab Reports<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/shop\/\">Shop<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/about\/\">About<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/faq\/\">FAQ<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/contact\/\">Contact<\/a>\n<\/div>\n\n<button class=\"menu-button\" type=\"button\" aria-expanded=\"false\" aria-controls=\"pdd-semaglutide-mobile-nav\" aria-label=\"Open navigation menu\">\n<svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M4 7h16M4 12h16M4 17h16\"><\/path><\/svg>\n<\/button>\n\n<nav class=\"mobile-nav\" id=\"pdd-semaglutide-mobile-nav\" aria-label=\"Mobile navigation\">\n<a href=\"https:\/\/peptidedeepdive.com\/research\/\">Research<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/peptide-coas\/\">Lab Reports<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/shop\/\">Shop<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/about\/\">About<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/faq\/\">FAQ<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/contact\/\">Contact<\/a>\n<\/nav>\n<\/div>\n<\/div>\n<main class=\"wrap\">\n<div class=\"article-hero\">\n<div class=\"breadcrumb\"><a href=\"https:\/\/peptidedeepdive.com\/\">Home<\/a> \/ <a href=\"https:\/\/peptidedeepdive.com\/research\/\">Research<\/a> \/ Semaglutide guide<\/div>\n<span class=\"r-badge\">GLP-1 pillar \u00b7 Evidence \u00b7 Regulation<\/span>\n<h1>Semaglutide: FDA &amp; EU Approval, Safety &amp; Evidence<\/h1>\n<p class=\"dek\">Semaglutide is the active ingredient in approved GLP-1 medicines including Ozempic, Rybelsus and Wegovy. This guide explains the evidence, current US and EU approvals, safety warnings, and why approved medicines are not interchangeable with compounded or research-labelled products.<\/p>\n<p class=\"article-meta\">PeptideDeepDive Editorial Team \u00b7 Updated 21 September 2026 \u00b7 Educational only<\/p>\n<\/div>\n<img data-recalc-dims=\"1\" alt=\"Semaglutide guide to FDA and EU approval\" class=\"hero-img\" decoding=\"async\" fetchpriority=\"high\" height=\"450\" src=\"https:\/\/i0.wp.com\/d8j0ntlcm91z4.cloudfront.net\/user_3GYMvT1tR5HC1gvee5MuSPX1OIk\/hf_20260822_174024_acbbc755-85e2-4aa2-92b1-e90882012db7.png?resize=800%2C450&#038;ssl=1\" width=\"800\">\n<p class=\"hero-caption\">Semaglutide is an active ingredient used in several prescription medicines. Approval is product- and indication-specific.<\/p>\n\n<div class=\"toc\">\n<p>In this semaglutide guide<\/p>\n<ol>\n<li><a href=\"#what-is-semaglutide\">What semaglutide is<\/a><\/li>\n<li><a href=\"#approved-products\">US and European approvals<\/a><\/li>\n<li><a href=\"#mechanism\">How semaglutide works<\/a><\/li>\n<li><a href=\"#trials-monitoring\">Trials and safety monitoring<\/a><\/li>\n<li><a href=\"#timeline\">Approval timeline<\/a><\/li>\n<li><a href=\"#safety\">Safety and label warnings<\/a><\/li>\n<li><a href=\"#research-peptides\">Semaglutide vs research peptides<\/a><\/li>\n<li><a href=\"#tirzepatide\">Semaglutide vs tirzepatide<\/a><\/li>\n<li><a href=\"#compounded\">Compounded and &#8220;research&#8221; products<\/a><\/li>\n<li><a href=\"#faq\">Semaglutide FAQ<\/a><\/li>\n<\/ol>\n<\/div>\n\n<article>\n\n<h2 id=\"what-is-semaglutide\">What is semaglutide?<\/h2>\n<p>Semaglutide is a modified peptide that acts like GLP-1, a natural gut hormone. In other words, it belongs to a group of medicines called GLP-1 receptor agonists.<\/p>\n<p>When blood sugar is high, semaglutide can help the body release insulin. It may also reduce glucagon, a hormone that raises blood sugar. In addition, it can slow stomach emptying and affect appetite. However, the active ingredient is only one part of a medicine. Each approved product has a set formula, strength, delivery method, label and quality process.<\/p>\n<p>Therefore, &#8220;semaglutide&#8221; can describe an active ingredient, while Ozempic, Rybelsus and Wegovy describe regulated products. That distinction matters. A vial sold online with a semaglutide label does not inherit the approvals of those medicines. For the wider drug-class picture, see our <a href=\"https:\/\/peptidedeepdive.com\/glp-1\/\">GLP-1 medicines comparison<\/a>.<\/p>\n\n<div class=\"info-row\">\n<div class=\"info-box\"><div class=\"label\">Drug class<\/div><strong>GLP-1 receptor agonist<\/strong><span>A peptide-based medicine that activates the GLP-1 receptor.<\/span><\/div>\n<div class=\"info-box\"><div class=\"label\">Approved formats<\/div><strong>Injection and tablets<\/strong><span>The exact formats and uses differ by brand and region.<\/span><\/div>\n<div class=\"info-box\"><div class=\"label\">Regulatory point<\/div><strong>Product-specific approval<\/strong><span>Approval does not cover unapproved copies or every proposed use.<\/span><\/div>\n<\/div>\n\n<h2 id=\"approved-products\">Which semaglutide products are approved in the US and Europe?<\/h2>\n<p>The FDA and European regulators assess named medicines. Therefore, they do not approve semaglutide as a broad, free-standing category.<\/p>\n\n<div class=\"table-scroll\" role=\"region\" aria-label=\"Semaglutide product approval comparison\" tabindex=\"0\">\n<table>\n<thead><tr><th>Product<\/th><th>Form<\/th><th>Core regulatory role<\/th><th>US \/ Europe snapshot<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>Ozempic<\/td><td>Injection<\/td><td>Type 2 diabetes, with added labelled risk-reduction uses in defined groups<\/td><td>Authorised in US and EU<\/td><\/tr>\n<tr><td>Rybelsus<\/td><td>Tablet<\/td><td>Type 2 diabetes; current labels must be checked for region-specific claims<\/td><td>Authorised in US and EU<\/td><\/tr>\n<tr><td>Wegovy<\/td><td>Injection<\/td><td>Weight management; additional labelled uses vary by regulator and date<\/td><td>Authorised in US and EU<\/td><\/tr>\n<tr><td>Wegovy tablets<\/td><td>Tablet<\/td><td>Oral weight-management formulation for adults<\/td><td>Authorised in US and EU<\/td><\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n<p><strong>Europe note:<\/strong> the EMA&#8217;s current Wegovy product information now includes tablets for adults as well as the injectable form. The tablet extension followed a positive CHMP opinion in May 2026 and was incorporated into the EU product information later in 2026. National availability and reimbursement can still differ.<\/p>\n\n<h3>Why the European distinction matters<\/h3>\n<p>In Europe, the European Medicines Agency reviews the scientific evidence for many medicines. Next, the European Commission decides whether to grant an EU-wide marketing authorisation. Even so, access can vary because each country makes its own pricing, funding and supply decisions.<\/p>\n<p>For example, Ireland, Germany, France and Spain can share an EU authorisation while applying different reimbursement or prescribing rules. As a result, &#8220;approved in Europe&#8221; does not always mean &#8220;available on the same terms in every European country.&#8221;<\/p>\n\n<h2 id=\"mechanism\">How does semaglutide work as a GLP-1 medicine?<\/h2>\n<p>Semaglutide binds to and activates the GLP-1 receptor. Its design also extends its action compared with native GLP-1.<\/p>\n<p>After the receptor becomes active, several linked effects can occur. For example, insulin release can rise when blood sugar is high, while glucagon release can fall. Stomach emptying may also slow, especially early in treatment. In addition, GLP-1 signals reach brain areas linked with appetite.<\/p>\n<p>These biological effects help explain the approved uses. However, a mechanism is not proof that a drug will help every person. Clinical trials must still show benefits and risks for a defined population, product and outcome.<\/p>\n\n<h2 id=\"trials-monitoring\">How is semaglutide trialled and monitored?<\/h2>\n<p>An approved semaglutide medicine moves through a formal drug-development process. Regulators then continue to monitor it after approval.<\/p>\n\n<div class=\"steps-row\">\n<span class=\"step-pill\">01 Preclinical research<\/span>\n<span class=\"step-pill\">02 Human clinical trials<\/span>\n<span class=\"step-pill\">03 Regulatory review<\/span>\n<span class=\"step-pill\">04 Controlled production<\/span>\n<span class=\"step-pill\">05 Post-market monitoring<\/span>\n<\/div>\n\n<h3>Clinical evidence before approval<\/h3>\n<p>First, drug developers study the molecule in the laboratory and in early models. Next, human trials test how the drug acts, whether it works and which risks appear. Regulators then review the full application, not only a headline result. They also check production standards and the proposed label.<\/p>\n<p>Semaglutide programmes include large trials in diabetes, weight management and cardiovascular outcomes. Later applications also supported added indications. Importantly, each claim has its own evidence package.<\/p>\n\n<h3>Safety monitoring after approval<\/h3>\n<p>Approval does not end safety work. In the US, the FDA collects reports about side effects, medicine errors and product quality. In Europe, national authorities, the EMA and its PRAC safety committee share this work.<\/p>\n<p>However, an individual report does not prove that a medicine caused an event. Reports may be incomplete or repeated. Therefore, regulators compare report patterns with trials, real-world studies and other evidence before they change advice or labels.<\/p>\n\n<h2 id=\"timeline\">Semaglutide approval timeline<\/h2>\n<p>This timeline shows why semaglutide sits in a different evidence and regulatory category from unapproved research peptides.<\/p>\n\n<div class=\"timeline\">\n\n<div class=\"t-item\">\n<div class=\"t-date\">2017<\/div>\n<h3>Ozempic receives its first US approval<\/h3>\n<p>The FDA approved injectable Ozempic for adults with type 2 diabetes. This approval created the first US semaglutide medicine.<\/p>\n<img data-recalc-dims=\"1\" alt=\"Ozempic semaglutide approval for type 2 diabetes\" class=\"t-img\" decoding=\"async\" height=\"450\" loading=\"lazy\" src=\"https:\/\/i0.wp.com\/d8j0ntlcm91z4.cloudfront.net\/user_3GYMvT1tR5HC1gvee5MuSPX1OIk\/hf_20260822_174024_acbbc755-85e2-4aa2-92b1-e90882012db7.png?resize=800%2C450&#038;ssl=1\" width=\"800\">\n<\/div>\n\n<div class=\"t-item\">\n<div class=\"t-date\">2019<\/div>\n<h3>Rybelsus becomes the first oral GLP-1 medicine<\/h3>\n<p>The FDA approved Rybelsus tablets for type 2 diabetes. It was the first orally administered GLP-1 receptor agonist product.<\/p>\n<img data-recalc-dims=\"1\" alt=\"Rybelsus oral semaglutide approval\" class=\"t-img\" decoding=\"async\" height=\"450\" loading=\"lazy\" src=\"https:\/\/i0.wp.com\/d8j0ntlcm91z4.cloudfront.net\/user_3GYMvT1tR5HC1gvee5MuSPX1OIk\/hf_20260819_201731_8a3caf4c-91ad-4ea8-b912-b28c45215d45.png?resize=800%2C450&#038;ssl=1\" width=\"800\">\n<\/div>\n\n<div class=\"t-item\">\n<div class=\"t-date\">2021<\/div>\n<h3>Wegovy is approved for chronic weight management<\/h3>\n<p>The FDA approved injectable Wegovy for defined adults with obesity or overweight. The EU later authorised Wegovy through its central system.<\/p>\n<img data-recalc-dims=\"1\" alt=\"Wegovy semaglutide approval for weight management\" class=\"t-img\" decoding=\"async\" height=\"450\" loading=\"lazy\" src=\"https:\/\/i0.wp.com\/d8j0ntlcm91z4.cloudfront.net\/user_3GYMvT1tR5HC1gvee5MuSPX1OIk\/hf_20260822_175343_4e4085c9-0563-4e9c-983f-6eb80bece79f.png?resize=800%2C450&#038;ssl=1\" width=\"800\">\n<\/div>\n\n<div class=\"t-item\">\n<div class=\"t-date\">2024<\/div>\n<h3>Wegovy gains a US cardiovascular risk-reduction indication<\/h3>\n<p>The FDA added an indication to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.<\/p>\n<img data-recalc-dims=\"1\" alt=\"Wegovy cardiovascular outcomes approval\" class=\"t-img\" decoding=\"async\" height=\"450\" loading=\"lazy\" src=\"https:\/\/i0.wp.com\/d8j0ntlcm91z4.cloudfront.net\/user_3GYMvT1tR5HC1gvee5MuSPX1OIk\/hf_20260822_175343_36cd3fcf-0c84-409b-bfe4-0068b9466581.png?resize=800%2C450&#038;ssl=1\" width=\"800\">\n<\/div>\n\n<div class=\"t-item\">\n<div class=\"t-date\">2025<\/div>\n<h3>Kidney and MASH indications expand the US labels<\/h3>\n<p>In January, the FDA added a kidney and heart-risk indication to Ozempic for adults with type 2 diabetes and chronic kidney disease. Then, in August, it approved Wegovy injection for certain adults with MASH without cirrhosis and moderate to advanced liver scarring. The agency used its accelerated approval pathway for that use.<\/p>\n<img data-recalc-dims=\"1\" alt=\"Semaglutide evidence for MASH and chronic kidney disease indications\" class=\"t-img\" decoding=\"async\" height=\"450\" loading=\"lazy\" src=\"https:\/\/i0.wp.com\/d8j0ntlcm91z4.cloudfront.net\/user_3GYMvT1tR5HC1gvee5MuSPX1OIk\/hf_20260822_175343_6e44cb50-9971-4d00-939f-1b87894bab5a.png?resize=800%2C450&#038;ssl=1\" width=\"800\">\n<\/div>\n\n<div class=\"t-item\">\n<div class=\"t-date\">2025\u20132026<\/div>\n<h3>Oral Wegovy is approved in the US and authorised in the EU<\/h3>\n<p>FDA approved Wegovy tablets in December 2025. In Europe, the CHMP recommended the oral formulation in May 2026 and the current EU Wegovy product information now includes tablets for adults. Availability and reimbursement still vary by country.<\/p>\n<\/div>\n\n<\/div>\n\n<h2 id=\"safety\">Semaglutide safety and monitoring<\/h2>\n<p>An approved medicine can have strong evidence and still carry meaningful risks. Approval means regulators judged that benefits outweigh known risks for the approved use and population.<\/p>\n\n<div class=\"callout\">\n<div class=\"label\">US boxed warning<\/div>\n<p>US semaglutide labels carry a boxed warning about thyroid C-cell tumours seen in rodents. In addition, the labels say people should not use these medicines if they or their family have had medullary thyroid carcinoma, a type of thyroid cancer. The same restriction applies to people with Multiple Endocrine Neoplasia syndrome type 2.<\/p>\n<\/div>\n\n<h3>Common and serious label issues<\/h3>\n<p>For example, nausea, vomiting, diarrhoea and constipation are common in semaglutide trials. Labels also describe less common but important risks. These include pancreas or gallbladder problems, kidney injury linked with fluid loss and low blood sugar with some medicine combinations. In addition, labels cover diabetic eye problems and the risk of stomach contents entering the airway during anaesthesia or deep sedation.<\/p>\n<p>In Europe, the EMA safety committee also concluded that NAION, an eye condition that can cause vision loss, is a very rare side effect of semaglutide medicines. Consequently, sudden vision loss needs urgent medical attention.<\/p>\n\n<h3>What monitoring means in practice<\/h3>\n<p>Therefore, a prescriber can review the approved use, medical history, other medicines and label warnings. They can also explain which symptoms need quick medical care. This guide does not replace that assessment.<\/p>\n\n<h2 id=\"research-peptides\">Semaglutide vs research-grade peptides<\/h2>\n<p>The main difference is not whether both molecules contain amino acids. The key difference is the evidence and regulatory framework around the finished product.<\/p>\n\n<div class=\"table-scroll\" role=\"region\" aria-label=\"Approved semaglutide versus research-grade comparison\" tabindex=\"0\">\n<table>\n<thead><tr><th>Question<\/th><th>Approved semaglutide medicine<\/th><th>Product sold as &#8220;research-grade&#8221;<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>Approved patient use?<\/td><td>Yes, for the product&#8217;s labelled indications<\/td><td>No approval follows from an RUO label<\/td><\/tr>\n<tr><td>Human evidence?<\/td><td>Regulator-reviewed clinical programme<\/td><td>No medicine-level approval is established by the label<\/td><\/tr>\n<tr><td>Manufacturing?<\/td><td>Defined controls, specifications and inspections<\/td><td>Quality can vary; medicinal GMP status is not assumed<\/td><\/tr>\n<tr><td>Patient instructions?<\/td><td>Official prescribing information and patient leaflet<\/td><td>No regulator-validated patient dose or indication<\/td><\/tr>\n<tr><td>Safety monitoring?<\/td><td>Formal medicine-safety monitoring and label updates<\/td><td>No matching product-specific system is guaranteed<\/td><\/tr>\n<tr><td>Supply route?<\/td><td>Prescription and authorised pharmacy supply<\/td><td>Often sold &#8220;not for human consumption&#8221;<\/td><\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n<p>In contrast, calling semaglutide a peptide does not place approved Wegovy or Ozempic in the same category as BPC-157, TB-500 or another unapproved research compound. For a fuller comparison, read <a href=\"https:\/\/peptidedeepdive.com\/fda-vs-research-gate\/\">research-grade vs approved medicines explained<\/a>. For laboratory-product quality questions, see our <a href=\"https:\/\/peptidedeepdive.com\/purity\/\">peptide purity and COA guide<\/a>.<\/p>\n\n<h2 id=\"tirzepatide\">Semaglutide vs tirzepatide: what is the high-level difference?<\/h2>\n<p>Semaglutide and tirzepatide both appear in approved metabolic medicines. However, they do not use the same receptor mechanism.<\/p>\n\n<div class=\"split-row\">\n<div class=\"split-box\"><h3>Semaglutide<\/h3><p>A GLP-1 receptor agonist. Approved products include Ozempic, Rybelsus and Wegovy, each with its own form and label.<\/p><\/div>\n<div class=\"split-box\"><h3>Tirzepatide (10mg \/ 30mg \/ 60mg)<\/h3><p>A dual GIP and GLP-1 receptor agonist. Approved products include Mounjaro and Zepbound for specific uses.<\/p><\/div>\n<\/div>\n\n<p>Importantly, trial groups, outcomes, doses and product labels differ. For that reason, percentages from separate trials cannot prove that one medicine is best for an individual. See the separate <a href=\"https:\/\/peptidedeepdive.com\/tirzepatide\/\">tirzepatide mechanism and regulatory guide<\/a> for more context.<\/p>\n\n<h2 id=\"compounded\">Approved, compounded and &#8220;research&#8221; semaglutide are not interchangeable<\/h2>\n<p>A compounded drug can serve a patient-specific need in limited legal circumstances. However, it is not an FDA-approved copy.<\/p>\n<p>FDA declared the US shortage of semaglutide injections resolved on 21 February 2025. The shortage-based enforcement windows for routine copies subsequently ended. FDA reiterated in April 2026 that section 503A generally restricts regular compounding of products that are essentially copies of commercially available drugs, except in limited patient-specific circumstances.<\/p>\n<p>In 2026, FDA also warned about unapproved GLP-1 products sold with labels such as &#8220;for research purposes&#8221; or &#8220;not for human consumption.&#8221; Such wording does not create an approved medicine. In April 2026, FDA additionally proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List after finding no clinical need for outsourcing facilities to compound them from bulk substances. That proposal is separate from approval of branded medicines.<\/p>\n\n<div class=\"callout\">\n<div class=\"label\">Practical regulatory point<\/div>\n<p><strong>Check the exact product, route, label and supply chain.<\/strong> An approved active ingredient does not make every compounded, copied or &#8220;research&#8221; version approved. In Europe, use the EMA product information and the relevant national authority. In the US, use Drugs@FDA and current FDA compounding notices.<\/p>\n<\/div>\n\n<h2 id=\"faq\">Semaglutide FAQ<\/h2>\n\n<div class=\"faq-item\">\n<h3>Is semaglutide FDA-approved?<\/h3>\n<p>Yes. FDA-approved semaglutide products include Ozempic, Rybelsus and Wegovy for specific labelled uses. Approval applies to the named product, formulation and indication; it does not make every product sold as semaglutide FDA-approved.<\/p>\n<\/div>\n<div class=\"faq-item\">\n<h3>Is semaglutide approved in Europe?<\/h3>\n<p>Yes. The European Union has authorised semaglutide medicines including Ozempic, Rybelsus and Wegovy for defined uses. Product forms, indications, reimbursement and availability can differ by country, so check the current EMA information and the relevant national medicines authority.<\/p>\n<\/div>\n<div class=\"faq-item\">\n<h3>Is semaglutide a peptide?<\/h3>\n<p>Semaglutide is a peptide-based GLP-1 receptor agonist. However, an approved semaglutide medicine is not the same regulatory category as an unapproved product labelled &#8220;research-grade&#8221; or &#8220;research use only.&#8221;<\/p>\n<\/div>\n<div class=\"faq-item\">\n<h3>How is semaglutide different from research-grade peptides?<\/h3>\n<p>Approved semaglutide products have regulator-reviewed evidence, defined manufacturing controls, prescribing information and post-market safety monitoring. A research-grade label does not provide a marketing authorisation, approved indication, validated patient dosing or the same medicine-level oversight.<\/p>\n<\/div>\n<div class=\"faq-item\">\n<h3>What is the difference between semaglutide and tirzepatide?<\/h3>\n<p>Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. Both active ingredients appear in approved prescription medicines, but their brands, indications, labels and evidence are not interchangeable.<\/p>\n<\/div>\n<div class=\"faq-item\">\n<h3>Does PeptideDeepDive recommend using semaglutide?<\/h3>\n<p>No. PeptideDeepDive provides educational information and does not recommend a medicine for an individual. A qualified prescriber should assess benefits, risks, contraindications and monitoring needs.<\/p>\n<\/div>\n\n<div class=\"callout\">\n<div class=\"label\">Editorial review standard<\/div>\n<p>This article was checked against current FDA and EMA product information, approval records and safety communications. PeptideDeepDive does not claim clinician review unless a named qualified medical reviewer has completed that review.<\/p>\n<\/div>\n\n<div class=\"refs\">\n<h3>Primary sources<\/h3>\n<ol>\n<li><a href=\"https:\/\/www.fda.gov\/patients\/learn-about-drug-and-device-approvals\/drug-development-process\">US FDA \u2014 The Drug Development Process<\/a>.<\/li>\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215256s033lbl.pdf\">US FDA \u2014 Wegovy prescribing information (2026)<\/a>.<\/li>\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2026\/215256Orig1s031.pdf\">US FDA \u2014 Wegovy labeling review noting tablet approval under NDA 218316 (2026)<\/a>.<\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wegovy\">European Medicines Agency \u2014 Wegovy EPAR<\/a>.<\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ozempic\">European Medicines Agency \u2014 Ozempic EPAR<\/a>.<\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rybelsus\">European Medicines Agency \u2014 Rybelsus EPAR<\/a>.<\/li>\n<li><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or\">US FDA \u2014 Wegovy cardiovascular risk-reduction indication (2024)<\/a>.<\/li>\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2025\/209637Orig1s025ltr.pdf\">US FDA \u2014 Ozempic chronic kidney disease approval letter (2025)<\/a>.<\/li>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash\">US FDA \u2014 Wegovy MASH indication (2025)<\/a>.<\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/news\/first-oral-glp-1-treatment-weight-management\">European Medicines Agency \u2014 CHMP opinion on oral Wegovy (2026)<\/a>.<\/li>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize\">US FDA \u2014 Semaglutide shortage resolution and compounding policy<\/a>.<\/li>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss\">US FDA \u2014 Concerns with unapproved GLP-1 products (2026)<\/a>.<\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy\">European Medicines Agency \u2014 NAION safety review<\/a>.<\/li>\n<\/ol>\n<\/div>\n\n<\/article>\n\n<section aria-labelledby=\"related-products-title\" class=\"related-products\">\n<h2 id=\"related-products-title\">Related metabolic research products<\/h2>\n<p class=\"related-intro\">These research-directory entries relate to the article&#8217;s GLP-1 comparison. They are not approved semaglutide medicines, treatment substitutes or recommendations for human use.<\/p>\n<div class=\"product-grid\">\n<article class=\"product-card\">\n<div class=\"product-image-wrap\"><img data-recalc-dims=\"1\" alt=\"Tirzepatide metabolic research product\" class=\"product-image\" decoding=\"async\" height=\"600\" loading=\"lazy\" src=\"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/TirzepitideProduct.png?resize=600%2C600&#038;ssl=1\" width=\"600\"><\/div>\n<div class=\"product-copy\">\n<div class=\"product-label\">Metabolic research<\/div>\n<h3>Tirzepatide<\/h3>\n<p>Dual GIP and GLP-1 research context. This listing is not an authorised Mounjaro or Zepbound medicine.<\/p>\n<div class=\"product-price\">\u20ac44.99\u2013\u20ac99.99<\/div>\n<div class=\"product-actions\"><a aria-label=\"View external supplier listing for Tirzepatide\" class=\"product-button\" href=\"https:\/\/balticpeptides.com\/product\/tirzepatide\/?sld=17\" rel=\"sponsored nofollow noopener\" target=\"_blank\">View Supplier Listing<\/a><a class=\"product-guide\" href=\"https:\/\/peptidedeepdive.com\/tirzepatide\/\">Read Tirzepatide Guide<\/a><\/div>\n<\/div>\n<\/article>\n<article class=\"product-card\">\n<div class=\"product-image-wrap\"><img data-recalc-dims=\"1\" alt=\"Retatrutide metabolic research product\" class=\"product-image\" decoding=\"async\" height=\"600\" loading=\"lazy\" src=\"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/RetaProduct.png?resize=600%2C600&#038;ssl=1\" width=\"600\"><\/div>\n<div class=\"product-copy\">\n<div class=\"product-label\">Metabolic research<\/div>\n<h3>Retatrutide (5\u201350mg)<\/h3>\n<p>Triple-agonist research context. Retatrutide is not an approved medicine in the US, UK or European Union.<\/p>\n<div class=\"product-price\">\u20ac49.99\u2013\u20ac159.99<\/div>\n<div class=\"product-actions\"><a aria-label=\"View external supplier listing for Retatrutide\" class=\"product-button\" href=\"https:\/\/balticpeptides.com\/product\/retatrutide\/?sld=17\" rel=\"sponsored nofollow noopener\" target=\"_blank\">View Supplier Listing<\/a><a class=\"product-guide\" href=\"https:\/\/peptidedeepdive.com\/retatrutide\/\">Read Retatrutide Guide<\/a><\/div>\n<\/div>\n<\/article>\n<article class=\"product-card\">\n<div class=\"product-image-wrap\"><img data-recalc-dims=\"1\" alt=\"NAD plus cellular energy research product\" class=\"product-image\" decoding=\"async\" height=\"600\" loading=\"lazy\" src=\"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/NADProduct.png?resize=600%2C600&#038;ssl=1\" width=\"600\"><\/div>\n<div class=\"product-copy\">\n<div class=\"product-label\">Cellular energy research<\/div>\n<h3>NAD+ (500mg \/ 1000mg)<\/h3>\n<p>Metabolism and cellular-energy research context. This supplier entry is for laboratory research only.<\/p>\n<div class=\"product-price\">\u20ac49.99\u2013\u20ac74.99<\/div>\n<div class=\"product-actions\"><a aria-label=\"View external supplier listing for NAD plus\" class=\"product-button\" href=\"https:\/\/balticpeptides.com\/product\/nad\/?sld=17\" rel=\"sponsored nofollow noopener\" target=\"_blank\">View Supplier Listing<\/a><a class=\"product-guide\" href=\"https:\/\/peptidedeepdive.com\/nad\/\">Read NAD+ Guide<\/a><\/div>\n<\/div>\n<\/article>\n<\/div>\n<p class=\"affiliate-note\"><strong>Affiliate disclosure:<\/strong> PeptideDeepDive may earn a commission from supplier links. Product listings are not medical recommendations. Prices reflect supplier data checked on 18 September 2026 and may change; an online research listing should not be confused with an authorised branded medicine.<\/p>\n<\/section>\n<\/main>\n\n\n<script>\n(function(){\n  var button=document.querySelector('.menu-button');\n  var mobileNav=document.getElementById('pdd-semaglutide-mobile-nav');\n\n  if(button&&mobileNav){\n    button.addEventListener('click',function(){\n      var open=mobileNav.classList.toggle('open');\n      button.setAttribute('aria-expanded',String(open));\n      button.setAttribute('aria-label',open?'Close navigation menu':'Open navigation menu');\n    });\n\n    mobileNav.addEventListener('click',function(event){\n      if(event.target.closest('a')){\n        mobileNav.classList.remove('open');\n        button.setAttribute('aria-expanded','false');\n        button.setAttribute('aria-label','Open navigation menu');\n      }\n    });\n\n    document.addEventListener('keydown',function(event){\n      if(event.key==='Escape'){\n        mobileNav.classList.remove('open');\n        button.setAttribute('aria-expanded','false');\n        button.setAttribute('aria-label','Open navigation menu');\n      }\n    });\n  }\n})();\n<\/script>\n\n<footer>\n<div class=\"wrap\">\n<a class=\"brand\" href=\"https:\/\/peptidedeepdive.com\/\"><img data-recalc-dims=\"1\" alt=\"PeptideDeepDive logo\" class=\"brand-logo\" decoding=\"async\" height=\"30\" loading=\"lazy\" src=\"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=30%2C30&#038;ssl=1\" width=\"30\"><\/a>\n<p>Educational content only. Not medical advice. Semaglutide is a prescription medicine. A qualified healthcare professional should assess treatment decisions, contraindications and monitoring needs.<\/p>\n<\/div>\n<\/footer>\n","protected":false},"excerpt":{"rendered":"<p>PeptideDeepDive Research Lab Reports Shop About FAQ Contact Research Lab Reports Shop About FAQ Contact Home \/ Research \/ Semaglutide guide GLP-1 pillar \u00b7 Evidence \u00b7 Regulation Semaglutide: FDA &amp; EU Approval, Safety &amp; Evidence Semaglutide is the active ingredient in approved GLP-1 medicines including Ozempic, Rybelsus and Wegovy. This guide explains the evidence, current <a href=\"https:\/\/peptidedeepdive.com\/nl\/semaglutide\/\" class=\"more-link\">&#8230;<span class=\"screen-reader-text\">  Semaglutide Guide: FDA-Approved GLP-1 vs Research Peptides<\/span><\/a><\/p>","protected":false},"author":282947824,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"{title}\n\n{excerpt}\n\n{url}","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_wpas_customize_per_network":false,"jetpack_post_was_ever_published":false},"categories":[1],"tags":[],"class_list":["post-530","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.5 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Semaglutide: FDA &amp; EU Approval, Safety &amp; Evidence (2026)<\/title>\n<meta name=\"description\" content=\"Semaglutide explained: FDA\/EU approvals, Ozempic, Wegovy and Rybelsus, safety warnings, compounded products and research-grade differences.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/peptidedeepdive.com\/nl\/semaglutide\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Semaglutide Guide: FDA-Approved GLP-1 vs Research Peptides\" \/>\n<meta property=\"og:description\" content=\"Semaglutide explained: FDA\/EU approvals, Ozempic, Wegovy and Rybelsus, safety warnings, compounded products and research-grade differences.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/peptidedeepdive.com\/nl\/semaglutide\/\" \/>\n<meta property=\"og:site_name\" content=\"PeptideDeepDive\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T13:47:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-23T15:20:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png\" \/>\n<meta name=\"author\" content=\"Laurynas Dabasinskas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laurynas Dabasinskas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/\"},\"author\":{\"name\":\"Laurynas Dabasinskas\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#\\\/schema\\\/person\\\/8aa4df0c53d17a692e53269a6aeb62c2\"},\"headline\":\"Semaglutide Guide: FDA-Approved GLP-1 vs Research Peptides\",\"datePublished\":\"2026-08-03T13:47:39+00:00\",\"dateModified\":\"2026-09-23T15:20:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/\"},\"wordCount\":2265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#\\\/schema\\\/person\\\/8aa4df0c53d17a692e53269a6aeb62c2\"},\"image\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/peptidedeepdive.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/PeptideDeepDiveLogo-transparent.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/\",\"url\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/\",\"name\":\"Semaglutide: FDA & EU Approval, Safety & Evidence (2026)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/peptidedeepdive.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/PeptideDeepDiveLogo-transparent.png\",\"datePublished\":\"2026-08-03T13:47:39+00:00\",\"dateModified\":\"2026-09-23T15:20:31+00:00\",\"description\":\"Semaglutide explained: FDA\\\/EU approvals, Ozempic, Wegovy and Rybelsus, safety warnings, compounded products and research-grade differences.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/#primaryimage\",\"url\":\"https:\\\/\\\/peptidedeepdive.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/PeptideDeepDiveLogo-transparent.png\",\"contentUrl\":\"https:\\\/\\\/peptidedeepdive.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/PeptideDeepDiveLogo-transparent.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/semaglutide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/peptidedeepdive.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Semaglutide Guide: FDA-Approved GLP-1 vs Research Peptides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#website\",\"url\":\"https:\\\/\\\/peptidedeepdive.com\\\/\",\"name\":\"PeptidesExplained\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#\\\/schema\\\/person\\\/8aa4df0c53d17a692e53269a6aeb62c2\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/peptidedeepdive.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#\\\/schema\\\/person\\\/8aa4df0c53d17a692e53269a6aeb62c2\",\"name\":\"Laurynas Dabasinskas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g\",\"caption\":\"Laurynas Dabasinskas\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g\"},\"sameAs\":[\"http:\\\/\\\/ldabasinskas2003-fozpm.wordpress.com\"],\"url\":\"https:\\\/\\\/peptidedeepdive.com\\\/nl\\\/author\\\/ldabasinskas2003\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Semaglutide: FDA & EU Approval, Safety & Evidence (2026)","description":"Semaglutide explained: FDA\/EU approvals, Ozempic, Wegovy and Rybelsus, safety warnings, compounded products and research-grade differences.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/peptidedeepdive.com\/nl\/semaglutide\/","og_locale":"nl_NL","og_type":"article","og_title":"Semaglutide Guide: FDA-Approved GLP-1 vs Research Peptides","og_description":"Semaglutide explained: FDA\/EU approvals, Ozempic, Wegovy and Rybelsus, safety warnings, compounded products and research-grade differences.","og_url":"https:\/\/peptidedeepdive.com\/nl\/semaglutide\/","og_site_name":"PeptideDeepDive","article_published_time":"2026-08-03T13:47:39+00:00","article_modified_time":"2026-09-23T15:20:31+00:00","og_image":[{"url":"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png","type":"","width":"","height":""}],"author":"Laurynas Dabasinskas","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"Laurynas Dabasinskas","Geschatte leestijd":"13 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/peptidedeepdive.com\/semaglutide\/#article","isPartOf":{"@id":"https:\/\/peptidedeepdive.com\/semaglutide\/"},"author":{"name":"Laurynas Dabasinskas","@id":"https:\/\/peptidedeepdive.com\/#\/schema\/person\/8aa4df0c53d17a692e53269a6aeb62c2"},"headline":"Semaglutide Guide: FDA-Approved GLP-1 vs Research Peptides","datePublished":"2026-08-03T13:47:39+00:00","dateModified":"2026-09-23T15:20:31+00:00","mainEntityOfPage":{"@id":"https:\/\/peptidedeepdive.com\/semaglutide\/"},"wordCount":2265,"commentCount":0,"publisher":{"@id":"https:\/\/peptidedeepdive.com\/#\/schema\/person\/8aa4df0c53d17a692e53269a6aeb62c2"},"image":{"@id":"https:\/\/peptidedeepdive.com\/semaglutide\/#primaryimage"},"thumbnailUrl":"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png","articleSection":["Uncategorized"],"inLanguage":"nl-NL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/peptidedeepdive.com\/semaglutide\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/peptidedeepdive.com\/semaglutide\/","url":"https:\/\/peptidedeepdive.com\/semaglutide\/","name":"Semaglutide: FDA & EU Approval, Safety & Evidence (2026)","isPartOf":{"@id":"https:\/\/peptidedeepdive.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/peptidedeepdive.com\/semaglutide\/#primaryimage"},"image":{"@id":"https:\/\/peptidedeepdive.com\/semaglutide\/#primaryimage"},"thumbnailUrl":"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png","datePublished":"2026-08-03T13:47:39+00:00","dateModified":"2026-09-23T15:20:31+00:00","description":"Semaglutide explained: FDA\/EU approvals, Ozempic, Wegovy and Rybelsus, safety warnings, compounded products and research-grade differences.","breadcrumb":{"@id":"https:\/\/peptidedeepdive.com\/semaglutide\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/peptidedeepdive.com\/semaglutide\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/peptidedeepdive.com\/semaglutide\/#primaryimage","url":"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png","contentUrl":"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png"},{"@type":"BreadcrumbList","@id":"https:\/\/peptidedeepdive.com\/semaglutide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/peptidedeepdive.com\/"},{"@type":"ListItem","position":2,"name":"Semaglutide Guide: FDA-Approved GLP-1 vs Research Peptides"}]},{"@type":"WebSite","@id":"https:\/\/peptidedeepdive.com\/#website","url":"https:\/\/peptidedeepdive.com\/","name":"PeptidesExplained","description":"","publisher":{"@id":"https:\/\/peptidedeepdive.com\/#\/schema\/person\/8aa4df0c53d17a692e53269a6aeb62c2"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/peptidedeepdive.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":["Person","Organization"],"@id":"https:\/\/peptidedeepdive.com\/#\/schema\/person\/8aa4df0c53d17a692e53269a6aeb62c2","name":"Laurynas Dabasinskas","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g","caption":"Laurynas Dabasinskas"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g"},"sameAs":["http:\/\/ldabasinskas2003-fozpm.wordpress.com"],"url":"https:\/\/peptidedeepdive.com\/nl\/author\/ldabasinskas2003\/"}]}},"jetpack_publicize_connections":[],"spectra_blocks_featured_image_url":null,"spectra_blocks_author_info":{"display_name":"Laurynas Dabasinskas","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g","author_link":"https:\/\/peptidedeepdive.com\/nl\/author\/ldabasinskas2003\/","description":""},"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/phlgTH-8y","jetpack-related-posts":[{"id":368,"url":"https:\/\/peptidedeepdive.com\/nl\/fda-vs-research-gate\/","url_meta":{"origin":530,"position":0},"title":"Research-Grade Peptides vs Approved Medicines in Europe","author":"Laurynas Dabasinskas","date":"augustus 3, 2026","format":false,"excerpt":"Research-Grade vs FDA-Approved Peptides (2026) PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Research \/ Regulation \/ Research Peptides vs Approved Medicines Europe-first regulatory comparison Research-Use Peptide VS Authorised Medicine Research-Grade vs FDA-Approved Peptides: What Actually Differs Research-grade and FDA-approved are not two\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"PeptideDeepDive logo","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":481,"url":"https:\/\/peptidedeepdive.com\/nl\/ghk-cu\/","url_meta":{"origin":530,"position":1},"title":"GHK-Cu Copper Peptide: What the Research Shows","author":"Laurynas Dabasinskas","date":"augustus 3, 2026","format":false,"excerpt":"What Is GHK-Cu? Copper Peptide Evidence & Safety (2026) PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact PeptideDeepDive \u2014 Skin & Repair What Is GHK-Cu? Copper Peptide Evidence, Safety & Uses GHK-Cu is a copper-binding tripeptide studied in skin, tissue-remodelling and cell-signalling research.\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"PeptideDeepDive logo","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":356,"url":"https:\/\/peptidedeepdive.com\/nl\/bpc-research\/","url_meta":{"origin":530,"position":2},"title":"7 Things to Know About BPC-157","author":"Laurynas Dabasinskas","date":"augustus 1, 2026","format":false,"excerpt":"BPC-157 Research: 7 Evidence Facts to Know (2026) PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Research \/ Individual Guides \/ 7 Things to Know About BPC-157 Guide \u00b7 Recovery BPC-157 Research: 7 Evidence Facts to Know in 2026 BPC-157 research is dominated\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"BPC-157 5mg 10mg and 20mg Baltic Peptides supplier listing","src":"https:\/\/i0.wp.com\/balticpeptides.com\/wp-content\/uploads\/2026\/07\/BPC10VIAL-300x300.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/balticpeptides.com\/wp-content\/uploads\/2026\/07\/BPC10VIAL-300x300.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/balticpeptides.com\/wp-content\/uploads\/2026\/07\/BPC10VIAL-300x300.png?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":536,"url":"https:\/\/peptidedeepdive.com\/nl\/wolverine-stack\/","url_meta":{"origin":530,"position":3},"title":"Wolverine stack","author":"Laurynas Dabasinskas","date":"augustus 3, 2026","format":false,"excerpt":"Wolverine Stack: BPC-157 + TB-500 Evidence & Risks (2026) PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Research \/ Peptide Stacks \/ Wolverine Stack Evidence comparison \u00b7 Europe BPC-157 VS TB-500 Wolverine Stack: BPC-157 + TB-500 Evidence, Safety & Risks The Wolverine Stack\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":556,"url":"https:\/\/peptidedeepdive.com\/nl\/purity\/","url_meta":{"origin":530,"position":4},"title":"Research Peptide Purity and Dosing Safety: What Remains Unknown","author":"Laurynas Dabasinskas","date":"augustus 1, 2026","format":false,"excerpt":"Research Peptide Purity: COAs, Testing & Safety (2026) PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Research \/ Safety & Risk \/ Purity & Dosing Safety Safety \u00b7 Regulation Research Peptide Purity: COAs, Testing & Safety Gaps What peptide purity percentages and Certificates\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"Laboratory quality-control scene representing research peptide purity, COA checks and batch testing","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-24-2026-10_53_24-PM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-24-2026-10_53_24-PM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-24-2026-10_53_24-PM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-24-2026-10_53_24-PM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-24-2026-10_53_24-PM.png?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":472,"url":"https:\/\/peptidedeepdive.com\/nl\/cjc\/","url_meta":{"origin":530,"position":5},"title":"CJC-1295 Peptide: DAC Evidence &amp; UK\/EU Status","author":"Laurynas Dabasinskas","date":"augustus 3, 2026","format":false,"excerpt":"CJC-1295 Peptide: DAC vs No DAC, Evidence & Safety (2026) PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Research \/ Individual Guides \/ CJC-1295 Guide \u00b7 GH\/IGF-1 Research \u00b7 Europe CJC-1295 Peptide: DAC vs No DAC, Evidence & Safety CJC-1295 is a GHRH\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"PeptideDeepDive logo","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/posts\/530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/users\/282947824"}],"replies":[{"embeddable":true,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/comments?post=530"}],"version-history":[{"count":12,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/posts\/530\/revisions"}],"predecessor-version":[{"id":1639,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/posts\/530\/revisions\/1639"}],"wp:attachment":[{"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/media?parent=530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/categories?post=530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/tags?post=530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}